http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008505846-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4746 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2004-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2008505846-A |
| titleOfInvention | Peptides that are selectively lethal to malignant and transformed mammalian cells |
| abstract | A composition comprising a peptide corresponding to all or part of amino acid residues 12-26 of human p53, which has selective lethality to malignant cells and transformed cells when fused with a transmembrane leader sequence. provide. The peptides are useful for treating neoplastic diseases in animals, preferably humans. Also provided is a method of treating a neoplastic disease in a patient by administering a peptide of interest fused at its carboxy terminus with a transmembrane leader sequence, in killing malignant, transformed or neoplastic cells in vitro. A method for assessing the efficacy level of a peptide of interest is also provided. To reduce proteolysis of a peptide of interest, one or more D-amino acids are present in the p53 portion and / or transmembrane leader sequence of the peptide of interest. In order to be able to substitute the corresponding L-amino acid and further make the subject peptide less proteolytic, the pseudo-peptide bond or retro-inverso pseudo-peptide bond is either a p53 sequence or a transmembrane leader sequence or both. Can be substituted with peptide bonds, and , Transmembrane leader sequence and p53 portion of the subject peptides, retro - inverso isomers and partially modified retro - may include inverso isomer. Such isomers are less susceptible to proteolysis and thus have a longer half-life. [Selection figure] None |
| priorityDate | 2004-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.